Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease & Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RETSAT drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RETSAT Recombinant Protein High purity (>95%), Endotoxin Controlled, Sequence Verified. Theoretical MW optimized for enzymatic assays. |
View RETSAT Products |
| Gene Delivery | RETSAT Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View RETSAT Products |
| Benchmark Ab | Anti-RETSAT Antibody Recombinant positive control for western blot, IHC, and ELISA validation. |
View RETSAT Products |
| Validator | RETSAT siRNA Set For specific knockdown verification in adipocyte differentiation assays. |
View RETSAT Products |
| Related Target A | PPARG Transcription factor regulating RETSAT expression; key regulator of adipogenesis. |
View PPARG Products |
| Related Target B | ALDH1A1 Upstream enzyme in the retinol metabolism pathway, synergistic in metabolic syndrome. |
View ALDH1A1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic activity validation of ER-bound protein | HEK293 expressed RETSAT preserves native post-translational modifications and folding. |
| Off-target screening against other oxidoreductases | Homolog panel proteins strictly verified by mass spectrometry to ensure assay specificity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live RETSAT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The exploration of RETSAT (Retinol Saturase) therapeutics is gaining momentum, with major players shifting focus from traditional metabolic pathways to targeted lipid-metabolism modulation in oncology and NAFLD/NASH. As first-generation small molecule inhibitors and RNAi therapies reach preclinical validation, the next wave of R&D is targeting the precise intersection of retinol metabolism and ferroptosis regulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Academic Collaboratives, Biotech Startups | NASH / NAFLD, Obesity | Enzymatic Assay (Need high-purity, active recombinant RETSAT protein) |
| RNAi / siRNA | Pharma Consortiums | Liposarcoma, Solid Tumors | Knockdown Validation (Need sequence-verified RETSAT siRNA sets) |
| Monoclonal Antibody | Oncology Biotechs | Metabolic Reprogramming in Cancer | Epitope Mapping (Need HEK293-expressed RETSAT with native glycosylation) |